DP
CUE icon

Diadema Partners’s Cue Biopharma CUE Stock Holding History

Diadema Partners’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.3K Buy
+4,400
New +$41.1K 0.01% 135

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return

Diadema Partners's CUE Position: Q1 2026 in Review

Diadema Partners opened a new position in Cue Biopharma (CUE) in Q1 2026: 4,400 shares worth $30.3K. The stake represents 0.01% of the portfolio and ranks #135 among its holdings.

55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Diadema Partners held 4,400 shares of Cue Biopharma worth $30.3K as of Q1 2026.
  • Cue Biopharma was a new Diadema Partners position in Q1 2026.
  • Cue Biopharma made up 0.01% of Diadema Partners's portfolio in Q1 2026, its #135 holding.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.